Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with Docetaxel and Epirubicin in Neoadjuvant Breast Cancer
NCT00604435Phase 2Completed
- Sponsor
- Xijing Hospital
- Start
- Feb 2008
- Primary completion
- Jan 2010
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of endostar in breast cancer, sponsored by Xijing Hospital. Started Feb 2008; status: completed.
02
Drugs
endostar
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00604435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604435.